ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Daiichi Sankyo Co., Ltd.

Business Summary

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2022 JPYUSD
Revenue1,044.89B9,298.45M
Gross Profit691,564M6,154.20M
Operating income73,027M649.86M
Income before tax73,387M653.06M
Net income66,972M595.98M
EBITDA131,272M1,168.18M
Diluted EPS34.900.31
Dividends Per Share270.24
Total Assets2,221.40B18,301.97M
Total liabilities870,527M7,172.21M
Total equity1,350.87B11,129.73M
Operating cash flow139,226M1,238.96M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 960,195M 929,717M 981,793M 962,516M 1,044.89B
Gross Profit 614,174M 565,112M 638,587M 624,227M 691,564M
Operating income 112,326M 90,461M 118,028M 80,179M 73,027M
Income before tax 81,021M 85,831M 141,164M 73,956M 73,387M
Net income 60,282M 93,410M 129,074M 75,957M 66,972M
EBITDA 159,006M 136,630M 170,639M 137,561M 131,272M
Diluted EPS 30.36 47.95 66.26 39.11 34.90
Dividends Per Share 23.33 23.33 23.33 26.99 27
Total Assets 1,897.75B 2,088.05B 2,105.61B 2,085.17B 2,221.40B
Total liabilities 764,709M 838,343M 791,549M 807,030M 870,527M
Total equity 1,132.98B 1,249.64B 1,305.80B 1,272.05B 1,350.87B
Operating cash flow 108,439M 92,033M 196,601M 192,207M 139,226M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 8,663.48M 8,383.78M 9,029.99M 9,075.42M 9,298.45M
Gross Profit 5,541.46M 5,095.93M 5,873.37M 5,885.74M 6,154.20M
Operating income 1,013.47M 815.73M 1,085.55M 755.99M 649.86M
Income before tax 731.02M 773.98M 1,298.34M 697.32M 653.06M
Net income 543.90M 842.33M 1,187.15M 716.18M 595.98M
EBITDA 1,434.65M 1,232.07M 1,569.44M 1,297.04M 1,168.18M
Diluted EPS 0.27 0.43 0.60 0.36 0.31
Dividends Per Share 0.21 0.21 0.21 0.25 0.24
Total Assets 17,844.41M 18,864.80M 19,504.59M 18,870.38M 18,301.97M
Total liabilities 7,190.49M 7,574.13M 7,332.21M 7,303.43M 7,172.21M
Total equity 10,653.33M 11,290.07M 12,095.86M 11,511.79M 11,129.73M
Operating cash flow 978.40M 829.91M 1,808.22M 1,812.29M 1,238.96M

Valuation Measures

Mar 2022
PER76.69
ROA3.11%
ROE5.10%
Operating margin6.98%
Profit margin6.40%

Key executives

  • President, CEO & Representative Director: Sunao Manabe
  • CFO, Director, Executive Officer & Head-Management: Hiroyuki Okuzawa
  • Global Director-Research & Development: Ken Takeshita
  • Head-Research & Development: Wataru Takasaki
  • Executive Officer & Head-Corp. Affairs Division: Hironobu Furuta

Shareholders

  • Nomura Asset Management Co., Ltd. (5.1%)
  • Capital Research & Management Co. (World Investors) (4.6%)
  • Nippon Life Insurance Co. (4.6%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.5%)
  • The Vanguard Group, Inc. (2.4%)
  • Mizuho Bank Pension Fund (2.2%)
  • Nikko Asset Management Co., Ltd. (2.1%)
  • Wellington Management Co. LLP (2.0%)
  • Daiwa Asset Management Co. Ltd. (2.0%)
  • The Shizuoka Bank Ltd. (1.6%)

Contact Details

  • Website:http://www.daiichisankyo.co.jp
  • Address: Daiichi Sankyo Head Office Bldg, A&B, 3-5-1 Nihonbashi-honcho, Tokyo, 103-8426, Japan
  • Phone: +81.3.6225.1111

Related Companies

  • Daiichi Sankyo Chemical Pharma Co., Ltd.
  • Daiichi Sankyo RD Novare Co., Ltd.
  • Daiichi Sankyo Biotech Co. Ltd.
  • Astellas Pharma, Inc. /3 Drug Products/
  • Daiichi Sankyo Belgium SA
  • Daiichi Sankyo Restricted Stock Compensation Plan
  • Daiichi Sankyo Pharma, Inc.
  • Novare Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Shanghai) Co. Ltd.
  • Daiichi Sankyo Venezuela SA
  • Daiichi Sankyo (Schweiz) AG
  • Daiichi Sankyo Hong Kong Ltd.
  • Daiichi Forging Dalian Co. Ltd.
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • Daiichi Sankyo Pension Fund
  • Daiichi Sankyo Espha Co., Ltd.
  • Daiichi Sankyo (Thailand) Ltd.
  • Daiichi Sankyo Employee Stock Ownership Plan
  • Daiichi Sankyo (China) Holdings Co., Ltd.
  • Daiichi Sankyo Ireland Ltd.
  • Sankyo Pharma Nederland BV
  • Daiichi Sankyo Taiwan Ltd.
  • NV Sankyo Pharma Belgium SA
  • Daiichi Sankyo Portugal Lda.
  • Daiichi Sankyo Austria GmbH
  • Daiichi Sankyo Nederland BV
  • Daiichi Sankyo Logistics Co. Ltd.
  • Daiichi Sankyo Italia SpA
  • U3 Pharma GmbH
  • Daiichi Sankyo Deutschland GmbH

Competitors

  • AstraZeneca PLC
  • Boryung Corporation
  • LegoChem Biosciences, Inc.
  • Reata Pharmaceuticals, Inc. Class A
  • Biomea Fusion Inc
  • ImmunoGen, Inc.
  • CHO Pharma, Inc.
  • Bolt Biotherapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • BioCardia, Inc.
  • Pyxis Oncology, Inc.
  • Aprea Therapeutics, Inc.
  • MacroGenics, Inc.
  • Qurient Co., Ltd.
  • Exelixis, Inc.
  • Nuvation Bio Inc Class A
  • Kymera Therapeutics, Inc.
  • Sutro Biopharma, Inc.
  • Heidelberg Pharma AG
  • Amphastar Pharmaceuticals Inc
  • Esperion Therapeutics, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • PTC Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Springworks Therapeutics, Inc.
  • Vincerx Pharma Inc
  • Aptose Biosciences Inc.
  • Blueprint Medicines Corp.
  • SELLAS Life Sciences Group, Inc.
  • Iovance Biotherapeutics Inc
Last Updated on 18 May, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more